Clinical perspectives of PSMA PET/MRI for prostate cancer

Authors

  • Felipe de Galiza Barbosa Hospital Sirio-Libanes. Departamento de Radiologia
  • Marcelo Araújo Queiroz Hospital Sirio-Libanes. Departamento de Radiologia
  • Rafael Fernandes Nunes Hospital Sirio-Libanes. Departamento de Radiologia
  • José Flávio Gomes Marin Hospital Sirio-Libanes. Departamento de Radiologia
  • Carlos Alberto Buchpiguel Hospital Sirio-Libanes. Departamento de Radiologia
  • Giovanni Guido Cerri Universidade de Sao Paulo. Faculdade de Medicina. Hospital das Clinicas. Instituto do Cancer do Estado de Sao Paulo

DOI:

https://doi.org/10.6061/clinics/2018/e586s

Keywords:

Prostate Cancer, Positron Emission Tomography/Magnetic Resonance Imaging, Diagnostic Imaging, Tumor Staging, Local Neoplasm Recurrence

Abstract

Prostate cancer imaging has become an important diagnostic modality for tumor evaluation. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has been extensively studied, and the results are robust and promising. The advent of the PET/magnetic resonance imaging (MRI) has added morphofunctional information from the standard of reference MRI to highly accurate molecular information from PET. Different PSMA ligands have been used for this purpose including 68gallium and 18fluorine-labeled PET probes, which have particular features including spatial resolution, imaging quality and tracer biodistribution. The use of PSMA PET imaging is well established for evaluating biochemical recurrence, even at low prostate-specific antigen (PSA) levels, but has also shown interesting applications for tumor detection, primary staging, assessment of therapeutic responses and treatment planning. This review will outline the potential role of PSMA PET/MRI for the clinical assessment of PCa.

Downloads

Download data is not yet available.

Downloads

Published

2019-02-15

Issue

Section

Review Articles

How to Cite

Barbosa, F. de G., Queiroz, M. A., Nunes, R. F., Marin, J. F. G., Buchpiguel, C. A., & Cerri, G. G. (2019). Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics, 73(Suppl. 1), e586s. https://doi.org/10.6061/clinics/2018/e586s